9s83 | pdb_00009s83

Crystal structure of de novo designed binder JUBO4 and the LEDGF PWWP domain

spinqualitylabelsall models 9s83, resolution 2.10Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights 9s83 is a 2 chain structure with sequence from Homo sapiens and Synthetic construct. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Method: X-ray diffraction, Resolution 2.1Å Ligands: EDO Resources: FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT Disease PSIP1_HUMAN Note=A chromosomal aberration involving PSIP1 is associated with pediatric acute myeloid leukemia (AML) with intermediate characteristics between M2-M3 French-American-British (FAB) subtypes. Translocation t(9;11)(p22;p15) with NUP98. The chimeric transcript is an in-frame fusion of NUP98 exon 8 to PSIP1/LEDGF exon 4. Function PSIP1_HUMAN Transcriptional coactivator involved in neuroepithelial stem cell differentiation and neurogenesis. Involved in particular in lens epithelial cell gene regulation and stress responses. May play an important role in lens epithelial to fiber cell terminal differentiation. May play a protective role during stress-induced apoptosis. Isoform 2 is a more general and stronger transcriptional coactivator. Isoform 2 may also act as an adapter to coordinate pre-mRNA splicing. Cellular cofactor for lentiviral integration. Publication Abstract from PubMed Lens epithelium-derived growth factor p75 (LEDGF/p75) is a chromatin reader that recognizes di- or trimethylated Lys36 of histone H3 (H3K36me2/3)-modified nucleosomes and is implicated in diverse diseases, including cancer and human immunodeficiency virus (HIV) infection. Inhibiting the interaction between the Pro-Trp-Trp-Pro (PWWP) domain of LEDGF and chromatin through a small-molecule drug presents an attractive therapeutic opportunity, but the compounds developed to date bind entirely within the small H3K36me2/3 pocket and achieve only modest affinity. Here, we report de novo computational design and structural validation of proteinaceous binders that engage both this canonical pocket and adjacent DNA-interacting surfaces of the PWWP domain. Using a hotspot-driven workflow integrating RFdiffusion, ProteinMPNN, AlphaFold, molecular dynamics simulations and manual structural assessment, we generated four protein designs that were subjected to experimental validation. Biophysical analysis confirmed that one designed binder had a low-micromolar affinity for the LEDGF PWWP domain. Another designed binder revealed unexpected homodimerization which apparently interfered with its binding to the target in solution. Nevertheless, this binder could be co-crystallized with the PWWP domain. The resulting atomic structure at 2.1 A resolution confirms correct engagement of the intended binding interface. This crystal structure enabled the construction of an expanded pharmacophore model that can instruct the design of next-generation small-molecule or peptide-based inhibitors targeting the LEDGF PWWP domain and related epigenetic readers. These results demonstrate that modern in silico design pipelines can directly yield functional proteinaceous binders without the need for additional experimental screening using phage display or related technologies. De novo design of proteinaceous binders targeting the LEDGF PWWP domain.,Vantieghem T, Delepine J, Noppen S, Beelen S, Drexler M, Holkova J, Houser J, Veverka V, Schols D, Strelkov SV Protein Sci. 2026 Aug;35(8):e70726. doi: 10.1002/pro.70726. PMID:42489162 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Proteopedia Page Contributors and Editors (what is this?)

OCA